Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-19 (Canceled)

Claim 20 (Currently Amended) A method for administering a biologically active ~~polypeptide~~ agent, the method comprising:

injecting ~~the~~ a formulation ~~of claim 17~~ comprising:

(a) an injection vehicle comprising hyaluronic acid dissolved in a physiological buffer at a concentration of about 0.01 to about 3 percent weight per volume; and

(b) particles comprising:

(i) the biologically active agent; and

(ii) a biocompatible polymeric matrix.

~~into a patient in need thereof through a 23-gauge or smaller needle, wherein the particles have an average diameter of between about 5 and about 200 microns.~~

Claim 21 (Canceled)

Claim 22 (Currently Amended) An injectable formulation, comprising:

(a) an ~~aggregation-reducing amount of~~ injection vehicle comprising hyaluronic acid dissolved in a physiological buffer at a concentration of about 0.01 to about 3 percent weight by volume; and

(b) particles, comprising:

(i) a biologically active agent, and

(ii) a biocompatible polymeric matrix~~, wherein the concentration of hyaluronic acid is about 0.01 to about 0.8 percent weight per volume~~.

Claim 23 (Currently Amended) The injectable formulation of claim ~~21~~ 22, wherein the ~~hyaluronic acid is dissolved in a~~ physiological buffer ~~comprising~~ comprises physiological saline.

Claim 24 (Canceled)

Claim 25 (Currently Amended) The injectable formulation of claim ~~21~~ 22, wherein the polymeric matrix comprises a blocked polymer.

Claim 26 (Currently Amended) The injectable formulation of claim ~~21~~ 22, wherein the polymeric matrix comprises an unblocked polymer.

Claim 27 (Currently Amended) The injectable formulation of claim ~~21~~ 22, wherein the polymer is a poly(lactide-co-glycolide).

Claim 28 (Currently Amended) The injectable formulation of claim ~~21~~ 22, wherein the biologically active agent is a polypeptide.

Claim 29 (Previously Presented) The injectable formulation of claim 28, wherein the polypeptide is selected from the group consisting of a growth hormone, a hepatocyte growth factor (HGF), a vascular endothelial growth factor (VEGF), a glucagon-like peptide I (GLP-I), a nerve growth factor, an insulin-like growth factor, and an antibody.

Claim 30 (Currently Amended) The injectable formulation of claim ~~21~~ 22, wherein the concentration of the polymeric matrix is about 1 mg/mL to about 500 mg/mL of formulation.

Claim 31 (Currently Amended) The injectable formulation of claim ~~21~~ 30, wherein the concentration of the polymeric matrix is about 1 mg/mL to about 300 mg/mL of formulation.

Claim 32 (Canceled)

Claim 33 (Currently Amended) The injectable formulation of claim ~~21~~ 22, wherein the hyaluronic acid is N-acylurea modified hyaluronic acid.

Claim 34 (Currently Amended) The injectable formulation of claim ~~21~~ 22, wherein the hyaluronic acid is sodium hyaluronate.

Claim 35 (Canceled)

Claim 36 (Previously Presented) The injectable formulation of claim 29, wherein the polypeptide is an anti-vascular endothelial growth factor Fab (anti-VEGF Fab).

Claim 37 (Canceled)

Claim 38 (Canceled)

Claim 39 (Canceled)

Claim 40 (New) The method of claim 20, wherein the concentration of hyaluronic acid is about 0.01 to about 1 percent weight per volume.

Claim 41 (New) The method of claim 40, wherein the concentration of hyaluronic acid is about 0.01 to about 0.8 percent weight per volume.

Claim 42 (New) The injectable formulation of claim 22, wherein the concentration of hyaluronic acid is about 0.01 to about 1 percent weight per volume.

Claim 43 (New) The injectable formulation of claim 42, wherein the concentration of hyaluronic acid is about 0.01 to about 0.8 percent weight per volume.

Claim 44 (New) A kit comprising:

(a) the formulation of claim 22; and

(b) an injection device comprising a 23-gauge or smaller needle.